Sonoma Pharmaceuticals, Inc.
SNOA
$5.09
$0.030.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.40% | 9.16% | 13.58% | 31.05% | -1.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.40% | 9.16% | 13.58% | 31.05% | -1.05% |
| Cost of Revenue | 22.35% | -5.20% | 36.71% | 27.40% | -6.21% |
| Gross Profit | 12.10% | 40.05% | -13.01% | 37.47% | 8.47% |
| SG&A Expenses | -2.19% | -15.21% | 10.04% | 2.59% | -5.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.96% | -9.03% | 15.39% | 12.44% | -2.21% |
| Operating Income | 6.65% | 53.44% | -22.16% | 29.64% | 5.40% |
| Income Before Tax | -24.57% | 61.15% | 0.43% | 64.33% | 31.29% |
| Income Tax Expenses | -100.68% | 184.93% | 115.79% | -20.97% | 542.42% |
| Earnings from Continuing Operations | -8.57% | 27.27% | -7.16% | 58.89% | 19.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.57% | 27.27% | -7.16% | 58.89% | 19.39% |
| EBIT | 6.65% | 53.44% | -22.16% | 29.64% | 5.40% |
| EBITDA | 6.61% | 54.31% | -24.91% | 29.92% | 5.10% |
| EPS Basic | 43.70% | 65.42% | 60.03% | 89.74% | 76.62% |
| Normalized Basic EPS | 35.40% | 81.52% | 62.87% | 91.10% | 80.07% |
| EPS Diluted | 43.70% | 65.42% | 60.03% | 89.74% | 76.62% |
| Normalized Diluted EPS | 35.40% | 81.52% | 62.87% | 91.10% | 80.07% |
| Average Basic Shares Outstanding | 92.83% | 110.30% | 168.13% | 300.78% | 244.81% |
| Average Diluted Shares Outstanding | 92.83% | 110.30% | 168.13% | 300.78% | 244.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |